遗传性血友病A的男性发病率约为1/5 000[1],其抑制物的产生率报道不一,累积发生率可达32.4%[2]。抑制物的产生导致凝血因子替代治疗无效、增加治疗费用及出血风险,成为临床治疗血友病面临的严重问题。抑制物的产生与多种因素有关,目前认为最密切相关的 The prevalence of hereditary hemophilia A in men is about 1/5 000 [1], and the incidence of inhibitors is reported in varying degrees, with a cumulative incidence of up to 32.4% [2]. Inhibitors lead to ineffective coagulation factor replacement therapy, increase the cost of treatment and bleeding risk, become a serious problem facing the clinical treatment of hemophilia. Inhibitors are associated with a variety of factors and are currently considered most relevant